Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Beer, Tomasz M
  • Biumenstein, Brent A
  • Fizazi, Karim
  • Hotte, Sebastien
  • Jacobs, Cindy
  • Stewart, Patricia S

publication date

  • May 20, 2013